Literature DB >> 33509976

Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China.

Xin Du1,2,3, Lizhu Guo1, Shijun Xia1, Jing Du4, Craig Anderson2,3,5,6, Hisatomi Arima7, Mark Huffman8, Yiqiang Yuan9, Yang Zheng10, Shulin Wu11, Xuefeng Guang12, Xianhui Zhou13, Hongbo Lin14, Xiaoshu Cheng15, Jianzeng Dong1,16, Changsheng Ma17.   

Abstract

OBJECTIVE: To determine AF prevalence and gaps in atrial fibrillation (AF) awareness and management in China.
METHODS: We conducted a community-based survey of 47 841 adults (age ≥45 years) in seven geographic regions of China between 2014 and 2016. Participants underwent a structured questionnaire, a standard 12-lead ECG, physical examination and blood sampling. AF prevalence, defined by either ECG detection or self-report, was estimated according to sampling weights, non-response and age and sex distribution of the population. We used multivariable logistic regression to estimate associations among sociodemographic, clinical and geographic factors with the AF prevalence, awareness and treatment.
RESULTS: The weighted AF prevalence was 1.8% (95% CI 1.7% to 1.9%), but varied from 0.9% to 2.4% across geographical regions and equates to being present in an estimated 7.9 (95% CI 7.4 to 8.4) million people in China. Among men and women, the AF prevalence increased from 0.8% and 0.6% in the age group 45-54 years to 5.4% and 4.9% in the age group ≥75 years, respectively. Proportions of people who were aware of having AF decreased overall from 65.3% in 45-54 year-olds to 53.9% in ≥75 year-olds and varied between sex (men 58.5%, women 68.8%) and residency status (urban 78.3%, rural 35.3%). Only 6.0% of patients with high-risk AF received anticoagulation therapy.
CONCLUSIONS: AF prevalence is higher than previously reported in China, with low awareness and large treatment gaps. Large-scale efforts are urgently needed to reduce AF adverse consequences. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  atrial fibrillation; epidemiology

Year:  2021        PMID: 33509976     DOI: 10.1136/heartjnl-2020-317915

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study.

Authors:  Shaobo Shi; Yanhong Tang; Qingyan Zhao; Hong Yan; Bin Yu; Qiangsun Zheng; Yigang Li; Liangrong Zheng; Yiqiang Yuan; Jingquan Zhong; Jian Xu; Yanqing Wu; Jing Xu; Lin Chen; Shufeng Li; Jian Jiang; Jingfeng Wang; Jie Fan; Minglong Chen; Baopeng Tang; Wei Li; Qiang Wu; Bei Shi; Shenghua Zhou; Xingsheng Zhao; Yuehui Yin; Zheng Zhang; Guoqiang Zhong; Xuebin Han; Fan Liu; Ming Wu; Lianjun Gao; Bo Yang; He Huang; Congxin Huang
Journal:  Lancet Reg Health West Pac       Date:  2022-04-11

Review 2.  Racial and Ethnic Considerations in Patients With Atrial Fibrillation: JACC Focus Seminar 5/9.

Authors:  Faye L Norby; Emelia J Benjamin; Alvaro Alonso; Sumeet S Chugh
Journal:  J Am Coll Cardiol       Date:  2021-12-21       Impact factor: 27.203

3.  Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study.

Authors:  Chi Zhang; Jia Wang; Ya Yang; Er-Li Ma; Hou-Wen Lin; Bing-Long Liu; Zhi-Chun Gu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

4.  Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study.

Authors:  Zhuxin Zhang; Chao Jiang; Liu He; Yu Bai; Jiahui Wu; Rong Hu; Qiang Lv; Man Ning; Li Feng; Ribo Tang; Caihua Sang; Deyong Long; Jianzeng Dong; Xin Du; Gregory Y H Lip; Changsheng Ma
Journal:  Clin Cardiol       Date:  2021-12-28       Impact factor: 2.882

5.  Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?

Authors:  Dong Lin; Yequn Chen; Jian Yong; Shiwan Wu; Yan Zhou; Weiping Li; Xuerui Tan; Ruisheng Liu
Journal:  Front Cardiovasc Med       Date:  2021-11-25

6.  The Transcultural Adaptation and Validation of the Chinese Version of the Duke Anticoagulation Satisfaction Scale.

Authors:  Yibo Wu; Shujie Dong; Xinyi Li; Haiping Xu; Xiaohui Xie
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

7.  Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes.

Authors:  Juan Wang; Yan-Min Yang; Jun Zhu; Han Zhang; Xing-Hui Shao
Journal:  Front Cardiovasc Med       Date:  2022-01-28

8.  Use of oral anticoagulants and its associated factors among nonvalvular atrial fibrillation patients with new-onset acute ischemic stroke: A report from the China Atrial Fibrillation Registry study.

Authors:  Jing-Rong Wang; Xin Du; Jian-Zeng Dong; San-Shuai Chang; Chao Jiang; Cai-Hua Sang; De-Yong Long; Ri-Bo Tang; Hai-Bin Zhang; Jin-Cheng Guo; Yu-Mei Wen; Liu He; Chang-Sheng Ma
Journal:  Clin Cardiol       Date:  2021-12-24       Impact factor: 2.882

9.  Elevated Peripheral T Helper Cells Are Associated With Atrial Fibrillation in Patients With Rheumatoid Arthritis.

Authors:  Xin Wang; Hongxuan Fan; Yongle Wang; Xufang Yin; Guangying Liu; Chong Gao; Xiaofeng Li; Bin Liang
Journal:  Front Immunol       Date:  2021-10-15       Impact factor: 7.561

10.  Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China.

Authors:  Hong-Qiu Gu; Xin Yang; Chun-Juan Wang; Xing-Quan Zhao; Yi-Long Wang; Li-Ping Liu; Xia Meng; Yong Jiang; Hao Li; Chelsea Liu; Yun-Yun Xiong; Gregg C Fonarow; David Wang; Ying Xian; Zi-Xiao Li; Yong-Jun Wang
Journal:  JAMA Netw Open       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.